Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects

Antiviral Therapy

Volumn 20, Issue 4, 2015, Pages 397-405

  Anderson, Matt S ^a   Gilmartin, Jocelyn ^a   Cilissen, Caroline ^b   De Lepeleire, Inge ^b   Van Bortel, Luc ^c   Dockendorf, Marissa F ^a   Tetteh, Ernestina ^a   Ancona, June K ^a   Liu, Rachael ^a   Guo, Ying ^a   Wagner, John A ^a   Butterton, Joan R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Merck Sharp and Dohme   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATINE KINASE; DORAVIRINE; MIDAZOLAM; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; CYP3A PROTEIN, HUMAN; CYTOCHROME P450 3A; PYRIDONE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIAZOLE DERIVATIVE;

ABDOMINAL DISCOMFORT; ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FOOD; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERTRANSAMINASEMIA; IRRITABILITY; LOOSE FECES; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MUSCLE SPASM; MUSCULOSKELETAL CHEST PAIN; NAUSEA; NECK PAIN; NORMAL HUMAN; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STIFF NECK; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; HALF LIFE TIME; LIQUID CHROMATOGRAPHY; METABOLISM; MIDDLE AGED; TANDEM MASS SPECTROMETRY;

ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP3A; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HALF-LIFE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDAZOLAM; MIDDLE AGED; PYRIDONES; REVERSE TRANSCRIPTASE INHIBITORS; TANDEM MASS SPECTROMETRY; TRIAZOLES;

EID: 84947550674     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2920     Document Type: Article

References (6)

1. de Béthune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res 2010; 85:75-90.
2. Lai MT. Antiviral activity and in vitro mutation development pathways of MK-1439: a novel non-nucleoside reverse transcriptase inhibitor (NNRTI). Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC). 9-12 September 2012, San Francisco, CA, USA. Abstract H551.
3. Vacca JP, Dorsey BD, Schleif WA, et al. L-735,524: an orally bioavailable human immuno-deiciency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A 1994; 91:4096-4100.
4. Bilello JA, Bauer G, Dudley MN, Cole GA, Drusano GL. Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-iber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob Agents Chemother 1994; 38:1386-1391.
5. Drusano GL, Moore KH, Kleim JP, Prince W, Bye A. Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through use of population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 2002; 46:913-916.
6. Morales-Ramirez JO, Gatell JM, Hagins DP, et al. Safety & antiviral effect of MK-1439, a novel NNRTI, (+TDF/ FTC) in ART-naive HIV infected patients. Conference on Retroviruses and Opportunistic Infections (CROI). 3-6 March 2014, Boston, MA, USA. Abstract 92LB.